Effect of Janus kinase inhibition by tofacitinib on body composition and glucose metabolism

• Material Type: 博士論文
• Title: Effect of Janus kinase inhibition by tofacitinib on body composition and glucose metabolism
• Author/Editor: Chikugo, Momoko; Sebe, Mayu; Tsutsumi, Rie; Iuchi, Marina; Kishi, Jun; Kuroda, Masashi; Harada, Nagakatsu; Nishioka, Yasuhiko; Sakaue, Hiroshi
• Author Heading: Chikugo, Momoko; Sebe, Mayu; Tsutsumi, Rie; Iuchi, Marina; Kishi, Jun; Kuroda, Masashi; Harada, Nagakatsu; Nishioka, Yasuhiko; Sakaue, Hiroshi
• Publication, Distribution, etc.: Faculty of Medicine Tokushima University
• Publication Date: 2018-08
• Publication Date (W3CDTF): 2018-08
• Alternative Title: ヤヌスキナーゼ阻害が体組成および糖代謝に与える影響; Effect of JAK inhibition on body composition
• Periodical title: The Journal of Medical Investigation
• No. or year of volume/issue: 65 3-4
• Volume: 65
• Issue: 3-4
• Pages: 166-170
• ISSN (Periodical Title): ISSN : 1349-6867; ISSN : 1343-1420
• Degree grantor/type: 徳島大学
• Date Granted: 2018-03-23
• Dissertation Number: 甲第3148号
• Degree Type: 博士（栄養学）
• Text Language Code: eng
• Subject Heading: Rheumatoid arthritis; Tofacitinib; Body composition; 関節リウマチ; 体組成
• Target Audience: 一般
• Note (General): Tofacitinib is the first Janus Kinase (JAK) inhibitor to treat moderately to severely active RA. In this study, we investigated whether the effect of tofacitinib have any effects on body composition in mice and female patients with RA. Female C57BL/6 mice fed with a high-fat diet were treated with 30 mg/kg/day tofacitinib or vehicle for 70 days. Following treatment, trunk muscle, subcutaneous fat, and visceral fats were measured using X-ray computed tomography CT scan. Glucose tolerance and insulin sensitivity were assessed. In female RA patients treated with biological disease modified anti-rheumatic-drugs (biological DMARDs) or tofacitinib (n=4 per group), we also evaluated the body composition after 3 months from the start of treatment initiation using bioelectrical impedance analysis. Treatment with tofacitinib did not affect the body weight, and body composition in C57BL/6mice. It also did not affect glucose, and insulin tolerance in mice. In patients with RA, treatment with biological DMARDs did not affect the body composition whereas the muscle mass was unchanged after receiving tofacitinib and the fat mass was significantly increased.
• Format (IMT): application/pdf
• Access Restrictions: インターネット公開
• Related Material (DOI): 10.2152/jmi.65.166
• Data Provider (Database): 国立情報学研究所 : 学術機関リポジトリデータベース（IRDB）（機関リポジトリ）; https://irdb.nii.ac.jp
• Original Data Provider (Database): 徳島大学 : 徳島大学機関リポジトリ

Table of Contents

http://repo.lib.tokushima-u.ac.jp/files/public/11/112232/20190722135419478548/k3148_abstract_review.pdf fulltext

http://repo.lib.tokushima-u.ac.jp/files/public/11/112232/20190730173959800691/k3148_fulltext.pdf fulltext